APA (7th ed.) Citation

Bosio, A., Cerretti, G., Padovan, M., Del Bianco, P., Polano, M., Mandruzzato, S., . . . Lombardi, G. (2025). Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: A phase II randomized controlled trial (the MIRAGE study). Trials, 26(1), 1. https://doi.org/10.1186/s13063-025-08997-2

Chicago Style (17th ed.) Citation

Bosio, Alberto, et al. "Regorafenib Versus Local Standard of Care in Patients with Grade 2–3 Meningioma No Longer Eligible for Loco-regional Treatments: A Phase II Randomized Controlled Trial (the MIRAGE Study)." Trials 26, no. 1 (2025): 1. https://doi.org/10.1186/s13063-025-08997-2.

MLA (9th ed.) Citation

Bosio, Alberto, et al. "Regorafenib Versus Local Standard of Care in Patients with Grade 2–3 Meningioma No Longer Eligible for Loco-regional Treatments: A Phase II Randomized Controlled Trial (the MIRAGE Study)." Trials, vol. 26, no. 1, 2025, p. 1, https://doi.org/10.1186/s13063-025-08997-2.